Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 15/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212255 | 0.97 | RAPGEF4 (0.60) | RAPGEF4LMNAALDH1A1FFAR4 | |
| Sulfuric Acid SCHEMBL28200703 | 0.84 | RAPGEF4 (0.46) | RAPGEF4LMNAALDH1A1FFAR4 | |
| SCHEMBL11334768 | 0.80 | RAPGEF4 (0.48) | RAPGEF4LMNAALDH1A1 | |
| SCHEMBL11774357 | 0.80 | RAPGEF4 (0.53) | RAPGEF4LMNAALDH1A1 | |
| Nitric Acid SCHEMBL28200780 | 0.80 | RAPGEF4 (0.43) | RAPGEF4LMNAALDH1A1FFAR4 | |
| Hydrochloric Acid SCHEMBL28019737 | 0.79 | RAPGEF4 (0.43) | RAPGEF4LMNAFFAR4 | |
| Hydrochloric Acid SCHEMBL8328636 | 0.79 | HTR1D (0.39) | RAPGEF4LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL26097882 | 0.77 | POLB (0.56) | RAPGEF4LMNAALDH1A1 | |
| SCHEMBL8327334 | 0.76 | HTR1D (0.40) | RAPGEF4ALDH1A1 | |
| SCHEMBL11982081 | 0.76 | RAPGEF4 (0.36) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113603619-B | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2023-02-10 | — | — | CN | claimed |
| US-20230398526-A1 | NITROGEN HETEROCYCLIC CARBENE CATALYST AND PREPARATION METHOD THEREFOR | PINGSHAN TRANSLATIONAL MEDICINE CENTER, SHENZHEN BAY LABORATOR (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230105618-A1 | IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-113603619-B | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-113480486-B | 3-amido-1, 2,4-triazole derivative and preparation method and application thereof | 赣南师范大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-113603619-A | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2021-11-05 | — | — | CN | disclosed |
| CN-113480486-A | 3-amido-1, 2,4-triazole derivative and preparation method and application thereof | 赣南师范大学 | 2021-10-08 | — | — | CN | disclosed |
| US-20200350503-A1 | IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| US-9593085-B2 | Blue luminescent compounds | LG CHEM, LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| WO-2016203350-A1 | IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-12-22 | — | — | WO | disclosed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0674631-B1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0959074-A2 | Substituted pyrazoles as CRF antagonists | PFIZER INC. (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5968944-A | TREATING STRESS AND ANXIETY RELATED DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958948-A | CORTICOTROPIN RELEASING FACTOR; THERAPY FOR STRESS | PFIZER, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5705646-A | Substituted pyrazoles as CRF antagonists | PFIZER INC. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0764153-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033727-A1 | SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0674631-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013661-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200350503-A1 | IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | PPOX, EHD1, INTS9 | RAPGEF4 3090/4885LMNA 2312/4885ALDH1A1 1611/4885 |
| US-20230105618-A1 | IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | PPOX, EHD1, INTS9 | RAPGEF4 3090/4885LMNA 2312/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.